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Toll-like receptors (TLRs) are the archetypal pattern
recognition receptors (PRRs) envisioned by Janeway
(1989) as innate sensors of pathogen attack and host
triggers of an adaptive immune response. Two recent
papers (Choe et al., 2005; Bell et al., 2005) reveal the
distinctive architecture of a TLR sensor domain and
hint at how this structural design facilitates the rec-
ognition of a wide array of pathogen molecules.
Molecules and mechanisms that perfectly fit the PRR
concept have emerged with great force in the past few
years, reshaping our view of vertebrate immunology
and showing deep evolutionary links with the defensive
measures of more primitive immune systems (Flajnik
and Du Pasquier, 2004; O’Neill, 2004). Chief among these
elucidated systems is the Toll pathway of Drosophila,
first studied for its role in embryonic patterning, then
unmasked in the adult fly as a critical component of
host defense against infection by fungi and gram-posi-
tive bacteria (Roach et al., 2005). And yet, the fly Toll
receptor is defiantly not a PRR. Instead, upstream
molecules perform the recognition task and thereupon
activate proteolytic cascades in the hemolymph that
cleave the secreted cytokine Spaetzle to a form that
binds Toll and triggers signaling (Weber et al., 2005).
The discovery of genes encoding eight additional Toll-
like receptors in the fly genome—along with seven ex-
tra Spaetzle-like ligands—fueled the idea of a broader
defensive shield triggered likewise, at a distance, by
other fly PRRs. To date, however, the majority of fly Toll
paralogs appear to work as developmental regulators,
and only Toll9 retains an immune signaling role (Weber
et al., 2005; Roach et al., 2005).
But the story in humans is very different. Thirteen
TLRs have been unearthed from mammalian genomes
(ten of which persist in humans; Roach et al., 2005),
and they are all genuine PRRs in the Janeway mold,
capable of discriminating among a harrowing array of
protozoan, fungal, bacterial, and viral invaders and of
signaling alarm into the cell via a core NF-κB pathway
(O’Neill, 2004; Kawai and Akira, 2005). How are these
immunological feats accomplished? Great strides have
been made in elucidating the signaling aspects, and we
now understand that there is a dedicated contingent of
adaptor molecules (headlined by the peripatetic MyD88)
that combinatorially engage TLR cytoplasmic domains
and link them to special IRAK family kinases, which in
turn drive the NF-κB activation cascade (Kawai and
Akira, 2005). Although we do know the crystal structure*Correspondence: jfbazan@gene.comof the characteristic TIR domain (named to mark this
region of homology between Toll and Interleukin-1 Re-
ceptors; Xu et al., 2000) that adorns both TLR intracel-
lular segments and adaptor molecules and dominates
their binding, we do not have in hand—yet!—a hetero-
meric TIR-TIR complex that reveals the structural basis
of specificity for the initiating event of the signaling cas-
cade. Still, experimental mapping of TLRs to private or
shared adaptors (TRIF, TRAM, TIRAP, and others) is
proceeding apace and has importantly led to the dis-
covery of secondary signaling pathways that spring
from receptor complexes and mobilize Interferon-regu-
latory factor (IRF)-class transcription factors alongside
(or sometimes, instead of) NF-κB. The convergence of
these TLR signals induces a profusion of genes encod-
ing proinflammatory and immune defense cytokines,
completing the task of alerting and shaping the adap-
tive immune response to follow (Kawai and Akira, 2005).
Now for the recognition part, whose cunning we posit
is more biochemical than immunological in nature.
From the first announcement that TLR4 was the likely
receptor for gram-negative bacterial lipopolysaccha-
ride (LPS) in mice and humans, there has been a grow-
ing sense of amazement at how this family of germline-
encoded, nonclonal receptors could encompass or
evolve the sufficient structural diversity to specifically
recognize a broad swath of chemically dissimilar li-
gands (O’Neill, 2004). The current (and incomplete; see
Kawai and Akira, 2005) tally includes molecules like
bacterial lipopeptides, peptidoglycans, glycolipids, li-
poteichoic acid and flagellin, fungal zymosan, viral CpG
DNA, single- and double-stranded (ds)RNA, and syn-
thetic or drug-like compounds that mimic natural li-
gands, like the antiviral imiquimod or the plant-derived
taxol. Gene-deletion experiments for 10 of the 12 mouse
TLRs have speeded the precise mapping of these path-
ogen-derived molecular inducers to their respective
binding receptors (Kawai and Akira, 2005; Roach et al.,
2005). What has not emerged from this arduous pro-
cess is the clarifying intuition that could reason or even
predict a given TLR’s ligand binding proclivities. So it
is from this perspective that we can appreciate the im-
pact of two papers, one from the Scripps Research In-
stitute (Choe et al., 2005) and the other from the Na-
tional Institutes of Health (NIH) (Bell et al., 2005), that
independently reveal the crystal structure of the human
TLR3 ectodomain with sufficiently rich detail (at 2.1 and
2.4 Å resolution, respectively) that we can perhaps start
to make sense of the TLR recognition puzzle.
Initial analyses of human TLR sequences suggested
the presence of degenerate leucine-rich repeats (LRRs)
across the 500–800 amino acid length of their extracel-
lular segments, a defining feature of the fly Toll recep-
tors (Roach et al., 2005). Molecular models refined the
idea that the TLR ectodomains would fold as an unin-
terrupted solenoidal array of 19–26 LRRs with a pro-
nounced curvature (Bell et al., 2003; Weber et al., 2004).
And indeed, that is what the TLR3 crystal structures
show: the 670 amino acid ectodomain flaunts a smooth
arrangement of 23 LRRs flanked by characteristic cys-
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348teine-rich N- and C-terminal capping modules (Choe et
al., 2005; Bell et al., 2005). The curvature of the horse-
shoe-shaped LRR fold is most reminiscent of the ecto-
domain structures of the Nogo receptor (He et al., 2003;
superposition by Choe et al., 2005) and follicle-stimu-
lating hormone receptor (FSHR; Fan and Hendrickson,
2005; our comparison), smaller 10 LRR arrays that
share a particular 24 residue repeat motif with TLR3.
This LRR type sports economical loops on the outer
(convex) face that lace together the inner, parallel β
strands to form a concave surface for the array. There
are two main protrusions from the regular TLR3 fold,
one a radially extended loop from LRR20, and the other
a sideways elbow jutting out from LRR12; other TLRs
exhibit similar insertions in other repeats (Bell et al.,
2003, 2005). Another layer of complexity is the visible
N-glycosylation: both the Scripps and NIH teams
solved their TLR3 structures from glycoproteins pro-
duced in insect cells, showing 8 and 11 glycan chains,
respectively, of 15 possible (Choe et al., 2005; Bell et
al., 2005). An interesting finding is that the inner cavity
of the TLR3 horseshoe has quadrants occluded by the
glycosylation, and parts of the convex surface are cov-
ered as well. Sequence analysis of the glycosylation
patterns of other TLRs suggests that this is a general
phenomenon with the family (Weber et al., 2004).
So where do these TLR3 structures place the likely
binding site for the natural viral ligand, dsRNA, or its
mimic, poly(I:C)? The dogma of structures past would
immediately flag the cavity created by the concave β
sheet: molecular images of ribonuclease inhibitor
curled around angiogenin, internalin around an E-cad-
herin domain, and platelet glycoprotein-IBα grasping a
von Willebrand factor A1 module convincingly intimate
that LRR arrays preferentially use their inner surfaces
to bind target proteins (Bell et al., 2003). Even Nogo
receptor and FSHR utilize their concave LRR faces to
bind their respective ligands (Schimmele and Pluck-
thün, 2005; Fan and Hendrickson, 2005). But in the
present case, have the PRR demands forced a novel
solution onto the TLR family? Sequence conservation,
hydrophobic analysis, and electrostatic potential mapped
to the TLR3 surface paint a flat, glycan-free side face
on the C-terminal half of the LRR array (following the
LRR12 elbow) as a likely interaction epitope; by con-
trast, the concave β sheet appears markedly acidic and
hence repulsive to nucleic acids. Here is where things
get interesting, as both the Scripps and NIH structures
capture a symmetric TLR3 dimer in the crystal with a
modest buried surface area ofw1150 Å2 partly encom-
passing the above interaction site, with locked LRR12
elbows. This forges a novel arrangement of reverse-
facing horseshoes that are dimerized at their lower
(C-terminal) ends (see Figure 1), parsimoniously recre-
ating a membrane bound tableau that could be physio-
logically relevant to signaling. This last point is impor-
tant, because experiments with chimeric receptors that
take advantage of heterologous ectodomains (CD4 in
the case of TLR4; Medzhitov et al., 1997; Ozinsky et
al., 2000) or intracellular segments (FcγRIIa for TLR3;
de Bouteiller et al., 2005) to respectively drive or mea-
sure association argue that TLRs form signaling dimers.
This is consistent with our notion that TLRs operate











































Sigure 1. The Proposed Dimer Architecture of the TLR3 Ectodomain
he crystallographic complex of TLR3 chains (PDB ID code 2A0Z;
ell et al., 2005) shows the protein surface colored by electrostatic
otential (red, positive; blue, negative charge) with N-glycan chains
n green. The proposed ligand binding groove is depicted by a dot-
ed orange ball; gray arrows mark possible rearrangements that
ould bring the C termini closer together, further open the binding
roove, and drive intracellular signaling by the receptor TIR do-
ains. Composed with Pymol (http://pymol.sourceforge.net/).ases in close proximity on the membrane (Stroud and
ells, 2004).
As promising as the TLR3 dimer appears in first light,
s it potentially an artifact of the common crystal form
sed by both the Scripps and NIH groups to solve their
-ray structures? Alternative packing schemes are em-
edded in the crystal lattice: for example, both data
ets disclose another symmetric TLR3 dimer that cen-
ers on a convex epitope around LRR8 and buries an
quivalent amount of surface area (w1170 Å2), but this
cheme seems biologically implausible, as the horse-
hoe C termini are splayed far apart. The present dimer
nterface shows poor surface complementarity, intru-
ion of water molecules, and juxtaposed charged resi-
ues—arguably features of a transient or forced en-
ounter. Still, we should not necessarily expect an
nbound receptor structure to fully recapitulate the li-
and-assembled version (Stroud and Wells, 2004); in
he case of TLRs, the critical test at this moment should
e how well this unorthodox architectural motif fits the
merging body of data on TLR association (Ozinsky et
l., 2000; de Bouteiller et al., 2005), ligand binding epi-
opes (Mizel et al., 2003; Grabiec et al., 2004; Omueti et
l., 2005), and coreceptor usage (Nishitani et al., 2005;
iang et al., 2005). This implies a broader utility of the
LR3 monomer (and proposed dimer) fold as a tem-
late for the remainder of the receptor family, with the
onviction that closely related molecules in sequence
nd structure tend to conserve their interaction modal-
ties (Aloy et al., 2003).
While the NIH group contemplates a binding groove
or dsRNA within the inner cavity of the TLR3 monomer
threading the nucleotide backbone through the posi-
ions of two bound sulfate ions; Bell et al., 2005), the
ost intriguing proposal—voiced more strongly by the
cripps contingent (Choe et al., 2005)—is that the TLR3
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349binding site for dsRNA is decidedly not on the concave
LRR surface. Instead, the ligand interaction site is sug-
gested to lie in the V-shaped valley between dimerized
structures, bridging basic patches of amino acids partly
occluded by the present dimer contact (Choe et al.,
2005; Bell et al., 2005). This simple solution may offer a
molecular explanation for the varied PRR activities of
TLRs, as these receptors could be utilizing the more
divergent loops, variable in sequence and length, on
the convex top and flat sides of the iconic horseshoe-
shaped fold to create diversity—and allowing different
receptor (homo- or hetero-) dimers to bind completely
different pathogen ligands. A corollary of this proposal
is that the sequence determinants responsible for li-
gand recognition and receptor oligomerization likely re-
side in the C-terminal half of the LRR arrays of TLRs,
leaving the N-terminal hook of the LRR fold free to po-
tentially interact with accessory molecules or core-
ceptors. Famously, for the best-studied TLR4-LPS sig-
naling complex, this offers sites for interaction with
another LRR array coreceptor, CD14, and MD2, an obli-
gate accessory molecule that solubilizes LPS (Nishitani
et al., 2005; Jiang et al., 2005). This structural scheme
is perhaps evolutionarily diverged from the recognition
of Spaetzle dimers by Drosophila Toll, whereby the re-
ceptors form an inactive pair in the absence of ligand
(utilizing their C-terminal LRR halves) but rearrange to
sequentially bind the cytokine dimer (with their N-ter-
minal LRR arrays) with a final stoichiometry of 2:2 re-
ceptor:ligand subunits (Weber et al., 2005). In the ab-
sence of Spaetzle equivalents in mammals, TLRs may
have coopted the inactive state of the Toll dimer as a
starting pose for pathogen recognition with their con-
vex surfaces (the arrangement captured by the TLR3
structures); subsequent rearrangements that pivot open
the current dimer (for example, allowing dsRNA access
to the basic patch above the contact point) could like-
wise favor N-terminal LRR interactions with host acces-
sory proteins.
TLR3 is a member of a specialized subset of TLRs
that recognize unmethylated viral nucleic acids in
acidic endosomal compartments (Kawai and Akira,
2005; Kariko et al., 2005). Of these receptors, persua-
sive measurements have been made of the direct bind-
ing of poly(I:C) to TLR3 (de Bouteiller et al., 2005) and
CpG oligodeoxyribonucleotides to TLR9 (Cornelie et
al., 2004; Rutz et al., 2004). In the present case, the
Scripps and NIH groups, respectively, show intriguing
glimpses at data of poly(I:C) and dsRNA binding to their
purified TLR3 ectodomains (Choe et al., 2005; Bell et
al., 2005), so in coming months we may hope to view
an exact solution to this TLR recognition puzzle. Com-
pleting the circle, ongoing biochemical and crystallo-
graphic studies of the Toll-Spaetzle complex by a group
of Cambridge investigators (Weber et al., 2005) may
also offer a glimpse into the wholesale evolutionary ref-
ormation of TLRs from cytokine receptors to true PRRs.
There are other LRR sensor proteins in our innate im-
mune arsenal (Flajnik and Du Pasquier, 2004), notably
the intracellular NLRs (for NACHT-LRRs, which collec-
tively group the NOD and NALP families, vertebrate
counterparts to plant Resistance proteins) that may
represent new PRR clans (Martinon and Tschopp,
2005). Taking cues from the TLR3 complex structure, itmay be useful to consider the unorthodox TLR dimer
architecture as a possible solution for other vexing LRR
recognition problems in nature; in addition, protein de-
sign efforts that are aimed at remodeling the inner, con-
cave surface of LRR arrays as all-purpose binding plat-
forms (Schimmele and Pluckthün, 2005) may broaden
their guiding principle of a single, evolutionarily mallea-
ble face to LRRs.
A parallel, oft-neglected family of innate immune
PRRs are the peptidoglycan recognition proteins (PGRPs),
that, among other things, sense infection by gram-nega-
tive bacteria and trigger the Immune Deficiency (Imd)
defense pathway in Drosophila (Flajnik and Du Pas-
quier, 2004). Crystallographic studies of human and fly
PGRP sensor domains directly in complex with pepti-
doglycan analogs are illuminating another primordial
mechanism of pathogen recognition and ligand-driven
PRR signaling (Chang et al., 2005). Together, the de-
veloping stories of TLRs and PGRPs attest to the mag-
nificent insight and immunological impact of Charles
Janeway’s PRRs (Janeway, 1989).
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